We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling

Law360 (January 4, 2019, 8:29 PM EST) -- The Federal Circuit on Friday said it wouldn’t reconsider the invalidation of four patents covering Acorda Therapeutics Inc.’s flagship multiple sclerosis drug Ampyra, despite the drugmaker’s argument that the decision had...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.